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checkpoint inhibitorsebased therapy as a potential surrogate end-point of progression-free
survival (PFS) and overall survival (OS) in patients with solid tumours, we performed a
trial-based meta-regression of randomised studies comparing different immune checkpoint in-
hibitorsebased treatments.
Methods: The systematic literature search included the electronic databases and the proceed-
ings of oncologic meetings. Treatment effects on PFS and OS were expressed as hazard ratios
(HRs); treatment effects on RR were expressed as odds ratios (ORs). A weighted regression
analysis was performed on log-transformed treatment effect estimates to test the association
between treatment effects on the surrogate outcome and treatment effects on the clinical
outcome.logy Unit, Department of Oncology, San Donato Hospital, Via Nenni 20, 52100 Arezzo, Italy.
o@hotmail.it (G. Roviello).
ts reserved.
G. Roviello et al. / European Journal of Cancer 86 (2017) 257e265258Results: Twenty-four trials, for a total of 11,894 patients, were included in the analysis. Using
the complete set of data, the regression of either the log(HR) for PFS or the log(HR) for OS
on the log(OR) for RR demonstrated weak associations (R2 Z 0.47; 95% confidence interval
[CI], 0.03e0.77; P Z 0.001; and R2 Z 0.32; 95% CI, 0.02e0.76; P Z 0.01, respectively). The
pre-planned analyses stratifying trials according to different type of disease and different
mechanism of action of immune checkpoint inhibitors showed a very weak association of
the RR with the OS for nonesmall cell lung cancer indicated and a modest association of
the RR with the PFS for cytotoxic T lymphocyteeassociated antigen 4 checkpoint inhibitors.
Conclusion: The results of the trial-based meta-regression analysis indicated a weak correla-
tion between RR and OS, supporting future investigations to assess the surrogacy of RR in
the patient treated with immune checkpoint inhibitors.
ª 2017 Elsevier Ltd. All rights reserved.1. Introduction
Over the past years, the main role played by the host’s
immune system and the activation of the host’s immune
effectors against cancer was under a deep research
focused on the discovery of the role of immunological
agents that are able to directly or indirectly generate a
potential immune response. Therefore, a new class of
drugs targeting the tumour microenvironment has
become available in clinic and has shown an unexpected
efficacy [1]. The first identified target was the cytotoxic T
lymphocyteeassociated antigen 4 (CTLA-4) receptor,
and ipilimumab is the first human monoclonal antibody
against CTLA-4 [2]. Recently, the discovery of new
antigens as the programmed cell death 1 (PD-1) in
activated T cells and its ligand PD-L1 in tumour cells
are the targets for the immunotherapeutic agent as
nivolumab, already tested in patients with various types
of advanced cancer [3]. Moreover, also pembrolizumab,
another checkpoint inhibitor, blocking the binding of
PD-1 and PD-L1 as well as PD-L2, showed a clear ef-
ficacy in several solid tumours [4]. Interestingly, with the
exception of ipilimumab, nivolumab and pem-
brolizumab seem to demonstrate objective response in
solid tumours other than melanoma or renal cancer
[4]. Owing to the important clinical impact in several
malignancies, new immune checkpoint inhibitors are in
the advanced stages of clinical development [4]. Recent
evidences indicated checkpoint-blocking monoclonal
antibodies not only represent a promising means to
induce robust and durable responses when employed as
single agents [4e8] but can also be harnessed to boost
the activity of several therapeutic regimens [9]. In this
scenario, the identification of a potential surrogate
marker for survival in patients under treatment with
novel immune checkpoint inhibitors would represent an
important advance in the early identification of patients’
response/resistance to a potential active therapy.
The assessment of the tumour change induced by the
treatment is an important issue for the clinical evalua-
tion of activity and efficacy of the administered therapy.
The Response Evaluation Criteria in Solid Tumours(RECIST) is a set of published rules defining when tu-
mours in cancer patients respond or not during treat-
ment [10]. According to the RECIST criteria, the
complete response and the partial response defined the
tumour response rate (RR) in phase III trials. Although,
in many clinical trials the tumour RR has been used as a
marker to guide treatment decisions on individual pa-
tients, the overall survival (OS) remained as the main
end-point for phase III trials and for the evaluation of
treatment efficacy. To assess the role of RR as a po-
tential surrogate of the clinical outcomes in patients
under treatment with the novel immune checkpoint in-
hibitors, we performed a systematic literature search and
a trial-based meta-regression analysis of randomised
controlled trials comparing different immune check-
point inhibitors in different solid tumours and the sur-
vival outcomes. The aim of this study was to assess
whether the treatment effects on tumour burden are able
to predict the long-term effects on survival of patients
receiving immune checkpoint inhibitors.
2. Methods
We planned a literature-based meta-regression analysis
of randomised controlled trials based on the use of the
novel immune checkpoint inhibitors. The primary
objective of the meta-analysis was the validation of the
RR as a potential surrogate end-point for efficacy
and survival meant as progression-free survival (PFS)
or OS in patients with solid tumours receiving the new
immune checkpoint inhibitors.
2.1. Identification of randomised trials
A systematic search of the literature was conducted to
identify all randomised trials based on the use of the
novel immune checkpoint inhibitors in solid tumours.
Relevant publications from PubMed and the Central
Register of Controlled Trials of the Cochrane Library
were identified. The search was focused on terms
describing novel immune checkpoint inhibitors; there-
fore, following medical subject heading terms were used:
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‘atezolizumab’ AND ‘solid tumours’ AND ‘prospective’
OR ‘clinical’ OR ‘random’. After the first search, article
types were chosen as follows: ‘clinical trial’ and
‘humans’ was chosen in PubMed, and no restrictions
were imposed in the Cochrane library. Publications
available in these databases up to February 28, 2017
were analysed. To minimise the risk of selection or in-
formation bias, the search criteria were limited to arti-
cles reporting the results of phase II or phase III
randomized controlled trials (RCT). The computer
search was supplemented with a manual search of the
primary studies referenced in all the retrieved review
articles. When the results of a study were reported in
subsequent analysis, only the most recent and complete
version was included in this meta-analysis. The detailed
flow diagram is reported in Fig. 1s Supplementary Data.
No restriction for language was set.
2.2. Eligibility criteria
Two authors (BP and PR) screened the studies according
to specific selection and exclusion criteria. Studies eligible
for the meta-analysis had to report RR and the survival
or efficacy outcomes in the different treatment arms. The
inclusion/exclusion decisions regarding contentious
studies were made in consultation with a third author
(GR). The studies were identified according to the
following inclusion criteria: 1) participants treated with
novel immune checkpoint inhibitors; 2) the presence of a
control arm for comparison without immune checkpoint
inhibitors (chemotherapy or placebo) and 3) a primary
outcome of OS and PFS. The following exclusion criteria
were used: 1) insufficient data were available to estimate
the outcomes; 2) the size of each arm was <10 partici-
pants and 3) non-randomised studies.
2.3. Data extraction
Two authors independently extracted the relevant data
including the name of the first author, publication year,
patient demographics (i.e. age, number, drug adminis-
tered and type of tumours), median follow-up, median
treatment duration, study design (i.e. the type of blind-
ing, the type of control and the methods for random-
isation), median OS and PFS and the number of patients
who experienced a RR. For each trial, the arm with
novel immune checkpoint inhibitors was considered to
be the experimental arm and chemotherapy or the
placebo control.
2.4. Statistical methods
The primary clinical outcomes were the PFS and OS. The
hazard ratio (HR) of disease progression and death be-
tween the experimental arm and the control arm was
used as the treatment effect estimated on the clinicaloutcome. The odds ratio (OR) of RR between the
experimental and the control arms was used as the
treatment effect estimated on the surrogate outcome. The
proportion of patients with an RR per treatment armwas
extracted from each single trial as the surrogate end-
point for the analysis. The statistical analysis consisted of
a weighted regression on a logarithmic scale between
treatment effects on the clinical outcomes and treatment
effects on the RR. For trials with multiple arms, a
contrast with the control arm was studied for any
experimental arm (i.e. the treatment effect was estimated
for any experimental arm versus the control arm).
A weighted regression analysis was performed on log-
transformed treatment effect estimates [i.e. log(HR)] to
test the association between treatment effects on the
surrogate outcome (RR) and treatment effects on the
clinical outcome (PFS or OS). The coefficient of deter-
mination (R2) was used to assess the goodness of fit for
each model and to quantify the surrogacy level of RR
[11e13]. 95% confidence intervals (CIs) of the R2 values
were estimated by bootstrap techniques. Moreover, due
to the different classes of immune checkpoint inhibitors
and the different types of considered tumours, a sub-
group analysis was performed according to these last
two subgroups. Data were acquired and analysed using
the R software (version 3.3.2) and the ‘boot’ package
(version 1.3e18) for the R2 bootstrapping.
3. Results
3.1. Trials included in the analysis
We identified 910 citations after the systematic search
(Fig. 1s). A total of 701 studies were excluded as du-
plicates. After viewing the titles and abstracts of the 109
remaining studies, the full texts of 46 studies were
retrieved and 17 studies [14e30] were included in the
analysis. The final set included a total of 8994 patients
(4947 in the experimental arm and 4047 in the control
arm) in the study. Three trials had two arms for a total
of 20 analysed arms. Main characteristics of included
trials are listed in Table 1. Five studies were on
nonesmall cell lung cancer, four on melanoma, three on
small-cell lung cancer, one on renal cancer, one on
prostate cancer and one on head and neck cancer.
Among the new experimental immune checkpoint in-
hibitors, nivolumab was the most represented drug. The
RECIST criteria were the most used standard for clas-
sifying tumour responses in the included trials (Table 1).
Data on PFS and OS along the median follow-up of the
included studies are reported in Table 2.
3.2. Analysis
The RR ranged from 11% to 62% in the experimental
group. Meanwhile, the RR ranged from 11% to 62% in
the control arm. Notably, in the experimental arm, the
Table 1
Trials included in the analysis.
Study Experimental
regimen
(number)
Control
regimen
(number)
Site Design Primary
end-point
System for
classifying
response
Borghaei et al., 2015 292 290 NSCLC Nivolumab versus docetaxel OS RECIST 1.1
Brahmer et al., 2015 135 137 NSCLC Nivolumab versus docetaxel OS RECIST 1.1
Ferris et al., 2016 240 121 Head & neck Nivolumab versus methotrexate/
docetaxel/cetuximab
OS RECIST 1.1
Herbst et al., 2016 344 343 NSCLC Pembrolizumab versus docetaxel OS & PFS RECIST 1.1
Herbst et al., 2016 (2) 346 343 NSCLC Pembrolizumab versus docetaxel OS & PFS RECIST 1.1
Know et al., 2014 399 400 Prostate Ipilimumab versus placebo OS Prostate cancer
clinical trials
working group’s
recommendations
& RECIST 1.0
Langer et al., 2016 60 63 NSCLC Pembrolizumab þ CHT versus CHT Objective
response
RECIST 1.1
Lynch et al., 2012 68 66 NSCLC Ipilimumab þ CHT versus CHT irPFS mWHO & irRC
Lynch et al., 2012 (2) 70 66 NSCLC Ipilimumab þ CHT versus CHT irPFS mWHO & irRC
Motzer et al., 2015 410 411 RENAL Nivolumab versus everolimus OS RECIST 1.1
Reck et al., 2013 43 45 SCLC Ipilimumab þ CHT versus CHT irPFS mWHO & irRC
Reck et al., 2013 (2) 42 45 SCLC Ipilimumab þ CHT versus CHT irPFS mWHO & irRC
Reck et al., 2016 478 476 SCLC Ipilimumab þ CHT versus
placebo þ CHT
OS mWHO
Reck et al., 2016 NEJM 154 151 NSCLC Pembrolizumab versus CHT PFS RECIST 1.1
Ribas et al., 2013 328 327 Melanoma Tremelimumab versus CHT OS RECIST 1.1
Ribas et al., 2015 180 179 Melanoma Pembrolizumab versus CHT PFS RECIST 1.1
Ribas et al., 2015 (2) 181 179 Melanoma Pembrolizumab versus CHT PFS RECIST 1.1
Robert et al., 2015 NEJM 210 208 Melanoma Nivolumab versus dacarbazine OS RECIST 1.1
Weber et al., 2015 272 133 Melanoma Nivolumab versus CHT Objective
response
RECIST 1.1
Bellmunt et al., 2017 270 272 Urothelial Pembrolizumab versus CHT OS & PFS RECIST 1.1
Rittmeyer et al., 2017 425 425 NSCLC Atezolizumab versus docetaxel OS RECIST 1.1
NSCLC, nonesmall cell lung cancer; CHT, chemotherapy; PFS, progression-free survival; OS, overall survival; WHO, World Health Organisation;
RECIST, Response Evaluation Criteria in Solid Tumours.
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The higher RR reported in the experimental group was
62% for ipilimumab plus chemotherapy [24]; the lower
RR was 4% with the use of tremelimumab [26].
We estimated the relationship between treatment ef-
fects on OS and treatment effects on RR and estimated a
regression equation. We regressed the log(HR) for OS on
the log(OR) for RR using the total number of events as
the weights in the weighted regression, demonstrating a
weak association between the two effects (R2 Z 0.47,
PZ 0.001). The equation of the resulting line (Fig. 1A) is
the following: log(HR)Z 0.1329e0.2575  log(OR).
The R2 value of the weighted regression line was 0.47
(95% CI, 0.03e0.77; PZ 0.001), indicating that the 47%
of the variability among the effects on OS can be
explained by the observed effects on RR.
We estimated the relationshipbetween treatment effects
on PFS versus treatment effects on RR and estimated a
regression equation.We regressed the log(HR) for PFS on
the log(OR) for RRusing the total number of events as the
weights in the weighted regression, demonstrating a weak
association between the two effects (R2Z 0.32, PZ 0.01).
The equation of the resulting line (Fig. 1B) is the following:
log(HR)Z 0.1281e0.2384  log(OR).The R2 value of the weighted regression line was 0.32
(95% CI, 0.02e0.76; P Z 0.01), indicating that the 32%
of the variability among the effects on PFS can be
explained by the observed effects on RR.
The surrogacy of RR was also explored in the pre-
planned analyses that are stratifying trials according to
different type of disease and different mechanism of ac-
tion of the immune checkpoint inhibitors. Regarding the
disease site, we performed the analysis separately by
nonesmall cell lung cancer (NSCLC) only because of the
limited samples available for the other type. As for the
mechanism of action of the considered checkpoint in-
hibitors, we performed the analysis for the group of anti-
CTLA-4 and the group of anti-PD-1/PD-L1 pathway.
The regression lines estimated for NSCLC indicated a
very weak association of the RR with the OS
(R2 Z 0.0007; 95% CI, 0.09e0.91; P Z 0.94; Fig. 2A)
and a weak association of the RR with the PFS
(R2 Z 0.42; 95% CI, 0.003e0.85; P Z 0.06; Fig. 2B).
The regression lines estimated for the subgroup related
to the use of the CTLA-4 checkpoint inhibitors indi-
cated a very weak association of the RR with the OS
(R2Z 0.00; 95% CI, 0.00e0.97; PZ 0.96; Fig. 2C) and
a modest association of the RR with the PFS
Table 2
Value of overall survival, progression-free survival and response rate of the included studies.
Study Median OS (months) Median PFS
(months)
Response rate (%)
Exp Cont Exp Cont Exp Cont
Borghaei et al., 2015 12.2 (9.7e15.0) 9.4 (8.1e10.7) 2.3 (2.2e3.3) 4.2 (3.5e4.9) 19 (15e24) 12 (9e17)
Brahmer et al., 2015 9.2 (7.3e13.3) 6.0 (5.1e7.3) 3.5 (2.1e4.9) 2.8 (2.1e3.5) 20 (14e28) 9 (5e15)
Ferris et al., 2016 7.5 (5.5e9.1) 5.1 (4.0e6.0) 2.0 (1.9e2.1) 2.3 (1.9e3.1) 13.3 (9.3e18.3) 5.8 (2.4e11.6)
Herbst et al., 2016 10.4 (9.4e11.9) 8.5 (7.5e9.8) 3.9 (3.1e4.1) 4.0 (3.1e4.2) 18 9
Herbst et al., 2016 (2) 12.7 (10.0e17.3) 8.5 (7.5e9.8) 4.0 (2.7e4.3) 4.0 (3.1e4.2) 18 9
Know et al., 2014 11.2 (9.5e12.7) 10.0 (8.3e11.0) 4.0 (3.6e4.3) 3.1 (2.9e3.4) 13.1 (9.5e17.5) 5.2 (3.0e8.4)
Langer et al., 2016 NR NR NR NR 55 (42e68) 29 (18e41)
Lynch et al., 2012 12.22 (9.26e14.39) 8.28 (6.80e12.39) 5.68 (4.76e7.79) 4.63 (4.14e5.52) 32 (22e45) 14 (6e24)
Lynch et al., 2012 (2) 9.69 (7.59e12.48) 8.28 (6.80e12.39) 5.52 (4.17e6.74) 4.63 (4.14e5.52) 21 (13e33) 14 (6e24)
Motzer et al., 2015 25.0 (21.8-ne) 19.6 (17.6e23.1) 4.6 (3.7e5.4) 4.4 (3.7e5.5) 25 5
Reck et al., 2013 9.13 (6.67e12.98) 9.92 (8.64e11.73) 3.89 (2.89e5.85) 5.19 (4.40e5.59) 33 (19e49) 49 (34e64)
Reck et al., 2013 (2) 12.94 (7.89e16.46) 9.92 (8.64e11.73) 5.22 (4.14e6.57) 5.19 (4.40e5.59) 57 (41e72) 49 (34e64)
Reck et al., 2016 11.0 (10.5e11.3) 10.9 (10.0e11.5) 4.6 (4.5e5.0) 4.4 (4.4e4.6) 62 (58e67) 62 (58e67)
Reck et al., 2016 NEJM NR NR 10.3 (6.7-ne) 6.0 (4.2e6.2) 44.8 (38.6e53.0) 27.8 (20.8e35.7)
Ribas et al., 2013 12.6 (10.8e14.3) 10.7 (9.36e11.96) 20.3 (15.9e24.6)
at 6 mo
18.1 (13.9e22.3)
at 6 mo
10.7 (7.8e14.9) 9.8 (6.8e13.5)
Ribas et al., 2015 NR NR 2.9 (2.8e3.8) 2.7 (2.5e2.8) 21 (15e28) 4 (2e9)
Ribas et al., 2015 (2) NR 2.9 (2.8e4.7) 2.7 (2.5e2.8) 25 (19e32) 4 (2e9)
Robert et al., 2015 NEJM NR 10.8 (9.3e12.1) 5.1 (3.5e10.8) 2.2 (2.1e2.4) 40.0 (33.3e47.0) 13.9 (9.5e19.4)
Weber et al., 2015 NR NR 4.7 (2.3e6.5) 4.2 (2.1e6.3) 31.7 (23.5e40.8) 10.6 (3.5e23.1)
Bellmunt et al., 2017 10.3 (8.0e11.8) 7.4 (6.1e8.3) 2.1 (2.0) 3.3 (2.2) 21.1 (16.4e26.5) 11.4 (7.9e15.8)
Rittmeyer et al., 2017 13.8 (11.8e15.7) 9.6 (8.6e11.2) 2.8 (2.6e3.0) 4.0 (3.3e4.2) 14 13
OS, overall survival; PFS, progression-free survival; NR, not reported.
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Finally, the regression lines estimated for the subgroup
of PD-1/PD-L1 checkpoint inhibitors indicated a weak
association of the RR with both OS (R2 Z 0.18; 95%
CI, 0.00e0.97; PZ 0.17; Fig. 2E) and PFS (R2Z 0.25;
95% CI, 0.02e1.00; P Z 0.08; Fig. 2F).
4. Discussion
To date, there is no consensus on the definition for valid
surrogate end-points for therapeutic benefits in patientsFig. 1. Treatment effect on tumour response versus oveunder treatment with immune checkpoint inhibitors.
While objective response is usually end-points in pa-
tients treated with chemotherapy and/or targeted ther-
apies, its value is not documented in patients treated
with immune therapies. The purpose of this analysis was
to identify potential surrogate end-points of response to
the new immune-modulating drug to predict the long-
term effect of the intervention on true end-point without
having to wait and observe the true end-point through a
strict and demonstrably correlation [31]. Unfortunately,
the discovery of the novel immune checkpointrall survival (A) and progression-free survival (B).
Fig. 2. Treatment effect on tumour response versus overall survival and progression-free survival for trials with nonesmall cell lung cancer
(NSCLC) (A and B), anti-CTLA-4 (C and D), and anti-PD-L1ePD pathway (E and F). IPI, ipilimumab; N, nivolumab; CHT,
chemotherapy.
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solid tumours, is very recent and therefore few data are
available for the prediction of response to novel check-
point inhibitors. Historically, the World Health Orga-
nisation (WHO) and the RECIST criteria are an
accepted approach for defining the disease response or
progression to systemic therapies [10,32]. Therefore, we
conducted a systematic search of all published rando-
mised controlled trials on novel immune checkpoint
inhibitors reporting information on both RR and sur-
vival to define the role of RR as a predictor of outcome
for patients exposed to novel immune checkpointinhibitors. With data extracted from a total of 17 trials,
we estimated the regression equation of the log(HR) for
the clinical outcome on the log(OR) for the RR. The
estimated regression equation showed a weak relation-
ship between the treatment effect on the RR and the
treatment effect on the clinical outcomes as the PFS and
the OS, suggesting that the activity of immune check-
point inhibitors on RR is able to explain almost 50% of
the effects detected on survival in patients with solid
tumours. Considering the heterogeneity of the patients’
cohort as the different type of solid tumours or treat-
ment and follow-up in the considered trials for the
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support the use of RR as a valid surrogate end-point to
be used in place of the true clinical end-points only in a
small subgroup of patients. Therefore, it might be
possible that patients’ responders to immune checkpoint
inhibitors likely will achieve some disease control but,
there are other factors that may help predicting the
impact of survival (e.g. immune biomarkers? mutational
tumour burden? and other clinical or biological factors).
The identification of the RR as surrogate end-point
capturing the treatment effect on survival or efficacy for
the checkpoint inhibitorsebased treatment would be
important for several reasons. First, the use of RR as a
surrogate end-point may facilitate the earlier analysis of
trial data, permitting to plan quicker and less expensive
studies. Second, although novel immune checkpoint
inhibitors have shown good efficacy in several tumours,
no data are available on the optimal time and duration
of these treatments and thus, the early evaluation of
response may be useful to individuate those patients
who are not responsive to immune checkpoint inhibitors
in an earlier phase and address them towards other
treatments.
Unfortunately, we are still waiting for a predictive
biomarker of response. Until now, one of the most
intriguing markers to identify potential responder to
novel immune checkpoint inhibitors is the evaluation of
the PD-L1 expression on formalin-fixed, paraffin-
embedded tumour section by immunohistochemistry
(IHC) [33]. However, the use of PD-L1 stained by IHC
is confounded by multiple unresolved issues such as the
variable detection antibodies, the differing cut-offs, the
tissue preparation, the processing variability, the pri-
mary versus metastatic biopsies, the oncogenic versus
induced PD-L1 expression and staining of tumour
versus immune cells [34]. Nevertheless, emerging data
are suggesting that patients, whose tumours are PD-
L1þ, have improved the clinical outcomes with anti-PD-
1edirected therapy. On the counterpart, the presence of
robust responses in some patients with low levels of PD-
L1 expression put in doubt the role of PD-L1 as a
predictive biomarker of response to the new immune-
modulating agents [35]. Moreover, a sensitivity analysis
aiming the evaluation of potential differential activity of
three different immune checkpoint inhibitors according
to the PD-L1 expression showed a significant interaction
between tumour PD-L1 expression and overall sample
with an RR of 34.1% in the PD-L1-positive and 19.9%
in the PD-L1-negative population. In particular, the
predictive value of PD-L1 on tumour cells seems to be
more robust with the anti-PD-1 antibody (nivolumab
and pembrolizumab), and with regards to the advanced
melanoma and NSCLC [35]. Other surrogate end-points
have been investigated such as baseline neutrophil-to-
lymphocyte ratio or peripheral CD8 effector-memory
type 1 T-cells [36,37] with an uncertainty on their use
as surrogate markers for OS and prospective validationsof these potential surrogates are required. Considering
all these data together, the 50% rate of prediction on
survival detected by our analysis seems to be relevant to
define future studies on immune checkpoint inhibitors.
In the near future, it might be possible that our data,
along with mutational tumour burden and/or PD-L1
expression, can help build a predictive model for longi-
tudinal evaluation of patients treated with immune
therapies.
Immunotherapy induces different patterns of response
compared with those related to chemotherapy, usually
evaluated with the RECIST or WHO criteria [10,32]. To
try to avoid possible differences, a consortium of
approximately 200 oncologists, immunotherapists and
regulatory experts developed the immune-related
response criteria (irRC) [38]. The most important dif-
ference between the irRC and RECIST or WHO criteria
is related to the concept of tumour burden, which re-
places the concept of target lesion. Therefore, the
changes are evaluated in all lesions, and the possible
appearance of new lesions are considered in the context
of the whole disease and not considered as a disease
progression (the thresholds to define progression are
different for irRC compared with RECIST or WHO
criteria). Unfortunately, the use of irRC is not well
standardised or largely used, and the majority of existing
trials used irRC as a corollary to the RECIST criteria.
However, in the absence of a consensus on this issue, the
RECIST criteria together with clinical conditions are the
most used criteria in clinical practice to guide treatment
decisions for patients treated with immune checkpoint
inhibitors.
Overall, analysing all the included studies, we
observed a non-negligible significant association be-
tween either OS or PFS and response [the former
measured using the log(HR) and the latter using the
log(OR)]. This implies that the response can be consid-
ered as a reliable potential surrogate for overall or PFS.
The results are qualitatively similar even if the total
number of events observed or with the total sample sizes
are used as the weights in the analysis.
However, splitting the study arms by site (NSCLC
versus all other sites) or by treatment (Atezo, nivo-
lumab, pembrolizumab (P), P þ chemotherapy
(CHT) versus ipilimumab (IPI), IPI þ CHT, trem-
elimumab), very little, if any, emerges about the
validity of the response as a potential surrogate for
overall or PFS.
Our analysis presents a few limitations we should
report: it was based on the literature rather than on in-
dividual patients’ data; on different chemotherapeutic
regimens, dosing and schedules reported in the various
analysed trials, onmainly different locations ofmetastatic
tumours and on different immune checkpoint inhibitors.
Therefore, although our total sample size is large, we
cannot yield safe and definitive conclusions. In addition,
one of the mayor criticism is that some patients treated
G. Roviello et al. / European Journal of Cancer 86 (2017) 257e265264with immune checkpoint inhibitors experienced an initial
increased size of tumour lesions with subsequent
decreased tumour burden. These findings of pseudo-
progression would have been classified prematurely as
progressive disease by RR in our analysed trials. How-
ever, the overall reported incidence of pseudoprogression
in solid tumours is low [39]; therefore, we deem that it only
marginally affects our analysis.
In conclusion, the results of this trial-based meta-
regression analysis indicated a weak correlation between
RR and OS; therefore, high and stringent criteria are
necessary to validate a surrogate end-point, which can
then be considered as a replacement end-point in future
investigations.
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